Levin Capital Strategies, L.P. Summit Therapeutics Inc. Transaction History
Levin Capital Strategies, L.P.
- $901 Million
- Q1 2025
A detailed history of Levin Capital Strategies, L.P. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Levin Capital Strategies, L.P. holds 36,176 shares of SMMT stock, worth $732,925. This represents 0.08% of its overall portfolio holdings.
Number of Shares
36,176
Previous 36,176
-0.0%
Holding current value
$732,925
Previous $645,000
8.06%
% of portfolio
0.08%
Previous 0.06%
Shares
6 transactions
Others Institutions Holding SMMT
# of Institutions
236Shares Held
86.8MCall Options Held
1.84MPut Options Held
3.13M-
Baker Bros. Advisors LP New York, NY24.4MShares$495 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$236 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$160 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$133 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$98.3 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.08B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...